HIV Infection, Human Immunodeficiency Virus 1 Positive, Malignant Neoplasm, Recurrent Malignant Neoplasm
Conditions
Brief summary
This trial studies the frequency of incident and prevalent of cancer in people living with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) at cancer centers in Latin America. By counting how many people living with HIV/AIDS have cancer at these specific centers, researchers may better understand how they are being treated and cared for. This may help researchers to understand what new studies may be helpful for those areas in the future.
Detailed description
PRIMARY OBJECTIVES: I. To determine the number of diagnosed cancers in people living with HIV/AIDS (PLWHA) presenting to participating clinical sites in Latin America, and estimate site-specific prevalence based on all presenting cancers (new diagnosis, recurrence, and surveillance cases) and site-specific incidence based on newly diagnosed cancers. SECONDARY OBJECTIVES: I. Obtain information on the use of diagnostic testing and treatment for the cohort of diagnosed HIV-associated cancer participants. II. To collect information on participant characteristics for diagnosed HIV-associated cancers (e.g., antiretroviral therapy \[ART\] regimen, current CD4 count, current viral load, etc.). OUTLINE: Patients respond to surveys and/or undergo medical record review at baseline and at 4 weeks.
Interventions
OTHERMedical Chart Review
Correlative studies
OTHERSurvey Administration
Respond to surveys
Sponsors
National Cancer Institute (NCI)
The Emmes Company, LLC
University of Arkansas
AIDS Malignancy Consortium
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HIV positive. Documentation of HIV-1 infection by means of any one of the following: * Documentation of receipt of ART by a licensed health care provider (Documentation may be a record of an ART prescription in the participant's medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant's name); * HIV-1 ribonucleic acid (RNA) detection by a licensed HIV-1 RNA assay demonstrating \> 1000 RNA copies/mL, and confirmed by a licensed screening antibody and/or HIV antibody/antigen combination assay; * Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay, such as a HIV-1 Western blot confirmation or HIV rapid multispot antibody differentiation assay. * Note: The term licensed refers to a kit that has been certified or licensed by an oversight body within the participating country and validated internally. * WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay or an E/Custom Industrial Analysis (CIA) that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load. * Must have a current or prior (within the last 5 years) diagnosis of cancer, but there is no restriction of the number or type of prior treatments. Participants will qualify under one of three categories: * New diagnosis: no prior treatment for current malignancy. May be prior to, or currently receiving the first line of therapy. * Prior diagnosis (within 5 years), in remission: Not currently on cancer treatment other than combination antiretroviral therapy (cART). Prior treatment for malignancy can include surgery, radiation, or chemotherapy (or cART initiation in Kaposi sarcoma \[KS\]). No restriction on number of prior lines of therapy. * Prior diagnosis, recurrent: considering or currently receiving treatment that is not first line. No restriction on the number of prior lines of therapy. * Date of birth and age should be determined based on best possible information or documentation available. * Ability to understand and the willingness to provide informed consent document.
Exclusion criteria
* Participants not meeting all criteria above are ineligible.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type | 21 months | The mean cases per month of prevalence will be estimated along with corresponding 95% Poisson confidence interval. The number of cases will be counted and mean cases per months will be estimated. Duration of observation was 21 months. This summary was based on the cancer type. |
| Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites | Up to 21 months | The primary endpoint will be the estimates of site-specific frequency of new diagnosis and existing cases (recurrence and surveillance) presenting with HIV and cancer presenting over 1 year, 9 months (21 months) at the clinical sites. |
| Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site. | 21 months | The mean cases per month of incidence will be estimated along with corresponding 95% Poisson confidence interval. The number of cases will be counted and mean cases per months will be estimated. Duration of observation was 21 months. This summary was based on the study site. |
| Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type. | 21 months | The mean cases per month of incidence will be estimated along with corresponding 95% Poisson confidence interval. The number of cases will be counted and mean cases per months will be estimated. Duration of observation was 21 months. This summary was based on the cancer type. |
| Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site. | 21 months | The mean cases per month of prevalence will be estimated along with corresponding 95% Poisson confidence interval. The number of cases will be counted and mean cases per months will be estimated. Duration of observation was 21 months. This summary was based on the study site. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Information on the Use of Diagnostic Testing in HIV-positive Individuals | Up to 21 months | The frequency of diagnostic testing modalities will be summarized for cancer. |
| HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer | Up to 21 months | For each cancer, summary statistics will be used to describe the HIV treatment regimens and disease characteristics. |
| Information on the Treatment for Cancers Diagnosed in HIV-positive Individuals | Up to 21 months | The frequency of the Treatment for Cancers Diagnosed in HIV-positive Individuals will be summarized. |
| CD4 of HIV-positive Individuals Diagnosed With Cancer | Baseline | CD4 percent of HIV-positive Individuals Diagnosed With Cancer will be summarized. |
| HIV Viral Load of HIV-positive Individuals Diagnosed With Cancer | Baseline | HIV viral load of HIV-positive Individuals Diagnosed With Cancer will be summarized |
Countries
Argentina, Brazil, Mexico
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Observational (Respond to Surveys, Medical Record Review) Patients respond to surveys and/or undergo medical record review at baseline and at 4 weeks.
Medical Chart Review: Correlative studies
Survey Administration: Respond to surveys | 175 |
| Total | 175 |
Baseline characteristics
| Characteristic | Observational (Respond to Surveys, Medical Record Review) |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 8 Participants |
| Age, Categorical Between 18 and 65 years | 167 Participants |
| Age, Continuous | 39 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 171 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 4 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 13 Participants |
| Race (NIH/OMB) Black or African American | 15 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 100 Participants |
| Race (NIH/OMB) White | 47 Participants |
| Region of Enrollment Argentina | 26 participants |
| Region of Enrollment Brazil | 49 participants |
| Region of Enrollment Mexico | 100 participants |
| Sex: Female, Male Female | 37 Participants |
| Sex: Female, Male Male | 138 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 0 |
| other Total, other adverse events | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 |
Outcome results
Primary
Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites
The primary endpoint will be the estimates of site-specific frequency of new diagnosis and existing cases (recurrence and surveillance) presenting with HIV and cancer presenting over 1 year, 9 months (21 months) at the clinical sites.
Time frame: Up to 21 months
Population: There are five study sites (Complexo Hospitalar; Hospital Fernandez; Hospital Roff0; Instituto Nacional De Cancer Brazil ; and Instituto de Oncologia). Given a study site, new diagnosis and existing cases(recurrence and surveillance) are summarized.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Observational (Respond to Surveys, Medical Record Review) | Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites | Complexo Hospitalar Professor Edgard Santos (new diagnosis) | 13 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites | Complexo Hospitalar Professor Edgard Santos (recurrence) | 4 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites | Complexo Hospitalar Professor Edgard Santos (surveillance) | 10 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites | Hospital Fernandez (new diagnosis) | 10 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites | Hospital Fernandez (recurrence) | 2 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites | Hospital Fernandez (surveillance) | 5 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites | Hospital Roffo (new diagnosis) | 3 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites | Hospital Roffo (recurrence) | 2 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites | Hospital Roffo (surveillance) | 4 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites | Instituto Nacional De Cancer Brazil (new diagnosis) | 11 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites | Instituto Nacional De Cancer Brazil (recurrence) | 2 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites | Instituto Nacional De Cancer Brazil (surveillance) | 9 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites | Instituto de Oncologia (new diagnosis) | 27 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites | Instituto de Oncologia (recurrence) | 9 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites | Instituto de Oncologia (surveillance) | 64 Participants |
Primary
Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type
The mean cases per month of prevalence will be estimated along with corresponding 95% Poisson confidence interval. The number of cases will be counted and mean cases per months will be estimated. Duration of observation was 21 months. This summary was based on the cancer type.
Time frame: 21 months
Population: The numbers of participants per cancer type were displayed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type | Kaposi sarcoma | 2.14 Mean cases per month |
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type | non-Hodgkin's Lymphoma | 1.33 Mean cases per month |
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type | Hodgkin's Lymphoma | 0.38 Mean cases per month |
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type | Anal cancer | 0.14 Mean cases per month |
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type | Cervical cancer | 0.14 Mean cases per month |
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type | Other | 1.14 Mean cases per month |
Primary
Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site.
The mean cases per month of prevalence will be estimated along with corresponding 95% Poisson confidence interval. The number of cases will be counted and mean cases per months will be estimated. Duration of observation was 21 months. This summary was based on the study site.
Time frame: 21 months
Population: The numbers of participants per study site were displayed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site. | Complexo Hospitalar Professor Edgard Santos | .67 mean cases per month |
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site. | Instituto Nacional De Cancer Brazil | 0.52 mean cases per month |
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site. | Instituto de Oncologia | 3.48 mean cases per month |
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site. | Hospital Fernandez | 0.33 mean cases per month |
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site. | Hospital Roffo | 0.29 mean cases per month |
Primary
Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type.
The mean cases per month of incidence will be estimated along with corresponding 95% Poisson confidence interval. The number of cases will be counted and mean cases per months will be estimated. Duration of observation was 21 months. This summary was based on the cancer type.
Time frame: 21 months
Population: The numbers of participants per cancer type were displayed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type. | Kaposi sarcoma (new diagnosis) | 1.19 Mean cases per month |
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type. | Non-Hodgkin's Lymphoma (new diagnisis) | 0.86 Mean cases per month |
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type. | Hodgkin's lymphoma (new diagnosis) | 0.24 Mean cases per month |
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type. | Anal cancer (new diagnosis) | 0 Mean cases per month |
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type. | Cervical cancer (new diagnosis) | 0.10 Mean cases per month |
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type. | Other (new diagnosis) | 0.67 Mean cases per month |
Primary
Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site.
The mean cases per month of incidence will be estimated along with corresponding 95% Poisson confidence interval. The number of cases will be counted and mean cases per months will be estimated. Duration of observation was 21 months. This summary was based on the study site.
Time frame: 21 months
Population: There are five study sites (Complexo Hospitalar; Hospital Fernandez; Hospital Roff0; Instituto Nacional De Cancer Brazil ; and Instituto de Oncologia). Given a study site, new diagnosis cases are summarized using cases per month.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site. | Complexo Hospitalar Professor Edgard Santos (new diasgnosis) | 0.62 New diagnosis cases per month |
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site. | Instituto Nacional De Cancer Brazil (new diagnosis) | 0.52 New diagnosis cases per month |
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site. | Instituto de Oncologia (new diagnosis) | 1.29 New diagnosis cases per month |
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site. | Hospital Fernandez (new diagnosis) | 0.48 New diagnosis cases per month |
| Observational (Respond to Surveys, Medical Record Review) | Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site. | Hospital Roffo (new diagnosis) | 0.14 New diagnosis cases per month |
Secondary
CD4 of HIV-positive Individuals Diagnosed With Cancer
CD4 percent of HIV-positive Individuals Diagnosed With Cancer will be summarized.
Time frame: Baseline
Population: 1 missing CD4 value
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Observational (Respond to Surveys, Medical Record Review) | CD4 of HIV-positive Individuals Diagnosed With Cancer | Kaposi sarcoma | 15 Percentage of CD4 cells |
| Observational (Respond to Surveys, Medical Record Review) | CD4 of HIV-positive Individuals Diagnosed With Cancer | Non-Hodgkin's lymphoma | 14.5 Percentage of CD4 cells |
| Observational (Respond to Surveys, Medical Record Review) | CD4 of HIV-positive Individuals Diagnosed With Cancer | Hodgkin's lymphoma | 17 Percentage of CD4 cells |
| Observational (Respond to Surveys, Medical Record Review) | CD4 of HIV-positive Individuals Diagnosed With Cancer | Anal | 18 Percentage of CD4 cells |
| Observational (Respond to Surveys, Medical Record Review) | CD4 of HIV-positive Individuals Diagnosed With Cancer | Cervical | 18 Percentage of CD4 cells |
| Observational (Respond to Surveys, Medical Record Review) | CD4 of HIV-positive Individuals Diagnosed With Cancer | Other | 26 Percentage of CD4 cells |
Secondary
HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer
For each cancer, summary statistics will be used to describe the HIV treatment regimens and disease characteristics.
Time frame: Up to 21 months
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Observational (Respond to Surveys, Medical Record Review) | HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer | Kaposi sarcoma (NNRTI only) | 17 Participants |
| Observational (Respond to Surveys, Medical Record Review) | HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer | Kaposi sarcoma (Combination) | 48 Participants |
| Observational (Respond to Surveys, Medical Record Review) | HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer | Kaposi sarcoma (No HIV treatment) | 5 Participants |
| Observational (Respond to Surveys, Medical Record Review) | HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer | Non-Hodgkin's lymphoma (NNRTI only) | 18 Participants |
| Observational (Respond to Surveys, Medical Record Review) | HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer | Non-Hodgkin's lymphoma (Combination) | 25 Participants |
| Observational (Respond to Surveys, Medical Record Review) | HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer | Non-Hodgkin's lymphoma (No HIV treatment) | 3 Participants |
| Observational (Respond to Surveys, Medical Record Review) | HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer | Hodgkin's lymphoma (NNRTI only) | 4 Participants |
| Observational (Respond to Surveys, Medical Record Review) | HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer | Hodgkin's lymphoma (Combination) | 8 Participants |
| Observational (Respond to Surveys, Medical Record Review) | HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer | Hodgkin's lymphoma (No HIV treatment) | 1 Participants |
| Observational (Respond to Surveys, Medical Record Review) | HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer | Anal (NNRTI only) | 1 Participants |
| Observational (Respond to Surveys, Medical Record Review) | HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer | Anal (Combination) | 2 Participants |
| Observational (Respond to Surveys, Medical Record Review) | HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer | Cervical (Combination) | 4 Participants |
| Observational (Respond to Surveys, Medical Record Review) | HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer | Cervical (No HIV treatment) | 1 Participants |
| Observational (Respond to Surveys, Medical Record Review) | HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer | Other (NNRTI only) | 21 Participants |
| Observational (Respond to Surveys, Medical Record Review) | HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer | Other (Combination) | 12 Participants |
| Observational (Respond to Surveys, Medical Record Review) | HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer | Other (No HIV treatment) | 5 Participants |
Secondary
HIV Viral Load of HIV-positive Individuals Diagnosed With Cancer
HIV viral load of HIV-positive Individuals Diagnosed With Cancer will be summarized
Time frame: Baseline
Population: 89 participants were assessed for this Outcome Measure.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Observational (Respond to Surveys, Medical Record Review) | HIV Viral Load of HIV-positive Individuals Diagnosed With Cancer | Kaposi sarcoma | 46 copies per ml |
| Observational (Respond to Surveys, Medical Record Review) | HIV Viral Load of HIV-positive Individuals Diagnosed With Cancer | Non-Hodgkin's lymphoma | 40.5 copies per ml |
| Observational (Respond to Surveys, Medical Record Review) | HIV Viral Load of HIV-positive Individuals Diagnosed With Cancer | Hodgkin's lymphoma49 | 49 copies per ml |
| Observational (Respond to Surveys, Medical Record Review) | HIV Viral Load of HIV-positive Individuals Diagnosed With Cancer | Anal | 30 copies per ml |
| Observational (Respond to Surveys, Medical Record Review) | HIV Viral Load of HIV-positive Individuals Diagnosed With Cancer | Cervical | 40.5 copies per ml |
| Observational (Respond to Surveys, Medical Record Review) | HIV Viral Load of HIV-positive Individuals Diagnosed With Cancer | Other | 40 copies per ml |
Secondary
Information on the Treatment for Cancers Diagnosed in HIV-positive Individuals
The frequency of the Treatment for Cancers Diagnosed in HIV-positive Individuals will be summarized.
Time frame: Up to 21 months
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Observational (Respond to Surveys, Medical Record Review) | Information on the Treatment for Cancers Diagnosed in HIV-positive Individuals | Surgery only | 3 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Information on the Treatment for Cancers Diagnosed in HIV-positive Individuals | surgery and chemotherapy | 2 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Information on the Treatment for Cancers Diagnosed in HIV-positive Individuals | Radiation only | 2 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Information on the Treatment for Cancers Diagnosed in HIV-positive Individuals | Radiation and chemotherapy | 3 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Information on the Treatment for Cancers Diagnosed in HIV-positive Individuals | Chemotherapy only | 24 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Information on the Treatment for Cancers Diagnosed in HIV-positive Individuals | Chemotherapy and other | 1 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Information on the Treatment for Cancers Diagnosed in HIV-positive Individuals | Other | 11 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Information on the Treatment for Cancers Diagnosed in HIV-positive Individuals | No information | 129 Participants |
Secondary
Information on the Use of Diagnostic Testing in HIV-positive Individuals
The frequency of diagnostic testing modalities will be summarized for cancer.
Time frame: Up to 21 months
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Observational (Respond to Surveys, Medical Record Review) | Information on the Use of Diagnostic Testing in HIV-positive Individuals | Histology (Kaposi sarcoma) | 62 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Information on the Use of Diagnostic Testing in HIV-positive Individuals | Clinical only (Kaposi sarcoma) | 7 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Information on the Use of Diagnostic Testing in HIV-positive Individuals | Histology (Non-Hodgkin's lymphoma) | 45 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Information on the Use of Diagnostic Testing in HIV-positive Individuals | Cytology (Non-Hodgkin's lymphoma) | 1 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Information on the Use of Diagnostic Testing in HIV-positive Individuals | Histology (Hodgkin's lymphoma) | 12 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Information on the Use of Diagnostic Testing in HIV-positive Individuals | Cytology (Hodgkin's lymphoma) | 1 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Information on the Use of Diagnostic Testing in HIV-positive Individuals | Histology(Anal) | 3 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Information on the Use of Diagnostic Testing in HIV-positive Individuals | Histology (Cervical) | 5 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Information on the Use of Diagnostic Testing in HIV-positive Individuals | Histology (Other) | 38 Participants |
| Observational (Respond to Surveys, Medical Record Review) | Information on the Use of Diagnostic Testing in HIV-positive Individuals | Unknown | 1 Participants |